Intestinal Microbiome Modification With Resistant Starch in Patients

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05691608` - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2	N/A
Recruiting	`NCT05580991` - Intratumoral CAN1012 in Subjects With Solid Tumors	Phase 1
Active, not recruiting	`NCT02846038` - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting	`NCT05159388` - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors	Phase 1/Phase 2
Completed	`NCT03181854` - Randomized Controlled Trial of Integrated Early Palliative Care	N/A
Recruiting	`NCT04107311` - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting	`NCT04078152` - Durvalumab Long-Term Safety and Efficacy Study	Phase 4
Completed	`NCT02250157` - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies	Phase 1
Recruiting	`NCT05566574` - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT05379946` - Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03943004` - Trial of DFP-14927 in Advanced Solid Tumors	Phase 1
Recruiting	`NCT05525858` - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting	`NCT05798546` - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)	Phase 1
Recruiting	`NCT04586335` - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.	Phase 1
Active, not recruiting	`NCT00479128` - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors	Phase 1
Recruiting	`NCT04143789` - Evaluation of AP-002 in Patients With Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 1/Phase 2
Not yet recruiting	`NCT04550663` - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors	Phase 1
Completed	`NCT03980041` - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)	Phase 2
Recruiting	`NCT04930432` - Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors	Phase 1/Phase 2

NCT number	NCT04552418
Study type	Interventional
Source	University of Michigan Rogel Cancer Center
Contact
Status	Completed
Phase	Early Phase 1
Start date	June 2, 2021
Completion date	January 24, 2023

Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms